M1 Kliniken AG

  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 12.09.2018 | 18:50

M1 Kliniken AG: M1 Kliniken AG successfully completes capital increase.

M1 Kliniken AG / Key word(s): Corporate Action/Capital Increase
M1 Kliniken AG: M1 Kliniken AG successfully completes capital increase.

12-Sep-2018 / 18:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) has successfully completed the capital increase in accordance with the resolutions passed on September 10, 2018 and today.
The Company increased its share capital by EUR 1,000,000.00 to EUR 17,500,000.00 by issuing a total of 1,000,000 no-par value bearer shares in exchange for cash contributions, to the exclusion of shareholders' statutory subscription rights, making partial use of authorized capital 2018. The new shares are entitled to dividends as of January 1, 2018.
The placement price determined by the Company's Management Board with the approval of the Supervisory Board was EUR 15.30 per share. The new shares were sold to institutional investors as part of an accelerated private placement process. Subject to registration of the capital increase in the commercial register, M1 Kliniken AG will receive gross proceeds of approximately EUR 15,300,000.00 from the capital increase.
The new shares are to be included in the open market trading of the Frankfurt Stock Exchange (Basic Standard) without a prospectus. Delivery and settlement of the new shares is expected to take place on September 17, 2018.
The capital increase was accompanied by B. Metzler seel. Sohn & Co. KGaA.

M1 Kliniken AG intends to use the proceeds from the capital increase to finance its expansion into new medical indications as well as the opening of additional M1-locations in Germany and abroad.
M1 Kliniken AG
The Board of Directors
About M1 Kliniken AG
M1 Kliniken AG is the leading private provider of health care services in the field of beauty medicine in Germany. In the field of aesthetic and surgical treatments, the Group offers products and services of the highest quality standards. Under the brand names "M1 Med Beauty" and "M1 Dental", a network of currently 20 ambulatory specialist centres for beauty treatments and a surgical clinic is operated. With six operating theatres and 35 beds, the M1 Schlossklinik Berlin is one of the largest and most modern facilities of ist kind in Europe. The Group also markets high-quality products to doctors, pharmacies and wholesalers.
Important information:
The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.

Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

12-Sep-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this


Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

Linde plc: Linde Announces Pricing of $1 Billion Notes

04. August 2020, 12:00

Aktueller Webcast

TeamViewer AG

Q2 2020 Ergebnis

04. August 2020

Aktuelle Research-Studie

artec technologies AG

Original-Research: artec technologies AG (von GBC AG): Kaufen

04. August 2020